Multiple Sclerosis Discovery Forum

Inspiring Connections

Sort By: Most Recent Article / Most Recent Comments / Most Comments

Podcasts | 8 Jun 2016

Episode 88 with Dr. John Hart on electrical stimulation for cognition in MS

Researchers are in the early stages of experimenting with electrical stimulation techniques to improve cognition in multiple sclerosis and other brain disorders. Don't try this at home, they caution.

MS Discovery

Clinical Research, Drug Development

Podcasts | 8 Jun 2016

Episode 87 with Dr. Ellen Mowry on testing restricted calorie diets in MS

Studies in animals and people have linked obesity to inflammatory diseases, such as multiple sclerosis. Researchers at Johns Hopkins University are testing calorie restriction for its safety and effectiveness in reducing disease severity in people with relapsing-remitting MS.

MS Discovery

Clinical Research

Podcasts | 6 Jun 2016

Episode 86 with Dr. Pavan Bhargava on targeting lesions lining the brain

Some people with MS have small long-lasting inflammatory lesions in the lining outside the brain, which may play a role in progressive disease. The discovery has prompted researchers to try to target these lesions more directly.

MS Discovery

Clinical Research, Drug Development

Podcasts | 27 May 2016

Episode 85 with Dr. Eva Havrdová on detecting a sub-optimal response to MS therapy

To preserve brain health in multiple sclerosis, research suggests the optimal treatment regime starts early and closely monitors patients by MRI if possible to switch therapies before a disabling relapse.

MS Discovery

Clinical Research, Drug Development

Podcasts | 25 May 2016

Episode 84 with Dr. Ilya Kister on stopping MS drugs & observational datasets

What happens to the course of multiple sclerosis when people stop taking their drugs? It depends on the individual and on the drug. A new study may help answer the question better.

MS Discovery

Clinical Research, Drug Development

Podcasts | 23 May 2016

Episode 83 with Dr. Jerry Wolinsky on composite clinical trial outcome measures

MS researchers have been looking to composite endpoints as more sensitive and meaningful measures of MS progression and disability for testing new drugs.

MS Discovery

Clinical Research, Drug Development

Podcasts | 20 May 2016

Episode 82 with Dr. Adam Kaplin on depression & MS

Depression may be the leading cause of disability and death among people with MS. Importantly, it's one of the few MS symptoms that can—and should— be completely reversed through treatment, says Adam Kaplin MD PhD.

MS Discovery

Clinical Research

Podcasts | 17 May 2016

Episode 81 with Dr. Kaarina Kowalec

Still in early days in MS, pharmacogenomics may have the potential optimize the risk/benefit profile in a patient's favor, focusing first on the risk of liver injury with interferon-beta.

MS Discovery

Clinical Research, Drug Development

Podcasts | 15 May 2016

Episode 80 with Dr. Kaarina Kowalec on adverse MS drug reactions

Approximately 1 in 50 people with MS in British Columbia, Canada, developed drug-induced liver injury with about three months of exposure to interferon-beta IFN-β. The study of adverse drug reactions will help minimize or prevent the toxicity of MS drugs, a major clinical objective.

MS Discovery

Clinical Research, Drug Development

Podcasts | 12 May 2016

Episode 79 with Dr. Nancy Monson on a diagnostic test to predict future risk for relapsing MS

Wouldn't it be great to be able to predict who will develop MS? A new diagnostic test based on mutated antibody genes in B cells can identify patients with clinically isolated syndrome who are at high risk of converting to relapsing MS.

MS Discovery

Clinical Research, Laboratory Research